News

ASCO issues advice on NEPA for CINV.

For oncology practitioners fielding questions from patients and survivors about breast cancer or genetics research news they've read online or through social media, a recently-launched news and information rating resource hopes to make that process easier.

The incidence of oropharyngeal cancers is growing-now surpassing cervical cancer-and the increase is expected to continue over the next 30 years, particularly for men currently aged ≤40 years.

Despite its safeguarding purpose, a new study has found that nearly half of healthcare personnel contaminated themselves while removing personal protective equipment (PPE).

ASCO issues updated statement on its use and healthcare provider education.

Women at an elevated risk of breast cancer may be able to avoid preventive procedures with regular aerobic exercise, according to a new study published in Breast Cancer Research and Treatment.

Targeted agents, such as afatinib (Gilotrif) and erlotinib (Tarceva), ushered in a new paradigm for treating patients with non-small cell lung cancer (NSCLC) who have an EGFR mutation.

Accelerated partial breast irradiation (APBI) using multicatheter brachytherapy in patients with early-stage breast cancer was not inferior to conventional whole breast irradiation (WBI), according to a phase III study presented at the 2015 American Society for Radiation Oncology (ASTRO) Annual Meeting.

The FDA has expanded the approval of Yervoy (ipilimumab) to include adjuvant treatment of fully resected stage III melanoma. The treatment will apply to patients with pathologic involvement of regional lymph nodes >1 mm.

Rates are on the rise for both men and women.

The FDA has approved the first-in-class oncolytic viral therapy Imlygic (T-VEC; talimogene laherparepvec) for the local treatment of unresectable lesions of the skin and lymph nodes in patients with melanoma that recurred after initial surgery.

As a 9-year testicular cancer survivor, I know the value of health insurance coverage and I choose my plan very carefully.

A study published recently in the Journal of Geriatric Oncology found that as many as 1 in 4 senior oncology patients were using complementary or alternative medicines (CAM), and the authors note that few oncology clinicians are sufficiently aware of the alternative medicines their patients take.

Radiation-induced flares of bone pain were significantly reduced in patients with metastatic cancer with the addition of dexamethasone, according to research presented at the 2015 ASTRO Annual Meeting.

Contralateral prophylactic mastectomies (CPM) have been a growing trend among women at average risk of breast cancer with a diagnosis of cancer in one breast, but the procedure is not medically recommended for this population.

In her role as division head of Occupational & Environmental Medicine at the University of Maryland, Melissa A. McDiarmid, MD, MPH, spends a lot of her time working with individuals who have been occupationally or environmentally exposed to toxic substances..

Trabectedin (Yondelis) chemotherapy was approved by the FDA for treatment of patients with specific metastatic soft tissue sarcomas-liposarcoma and leiomyosarcoma-who previously received chemotherapy that included an anthracycline.

The FDA has approved MM-398, branded as Onivyde (irinotecan liposome injection) in combination with 5-fluorouracil (5-FU) chemotherapy and leucovorin for patients with metastatic pancreatic cancer. The treatment follows prior administration of a gemcitabine-based regimen.

Despite having significantly elevated risks of long-term health problems, many cancer survivors eat poorer-quality diets than the general population.

The American Cancer Society (ACS) has revised its breast cancer screening guidelines, recommending that women at an average risk of breast cancer receive a mammography annually starting at age 45-5 years later than previous recommendations formulated in 2003.

New evidence suggests that there may be a safe and effective treatment option for older patients with Hodgkin lymphoma who are ineligible for chemotherapy.

SonaCare Medical's Sonablate 450 ultrasound device has received de novo clearance by the FDA for ablation of prostate tissue.

Not always reported by men with prostate cancer.

Debilitating neuropathy led to Mark's diagnosis of WM, and he has been subjected to many rounds of plasmapheresis and a number of demanding treatments without great success.

The majority of survivors and patients with cancer want to work but are faced with common challenges such as fatigue, managing side effects, and taking longer to complete work tasks, a recent survey has found.

Last month, we got the chance to discuss DCIS with three doctors from NYU Cancer Center: Dr. Deborah Axelrod, Dr. Julia Smith, and Dr. David Kleinberg.

Choose less, weigh less

Regardless of breast cancer subtype or stage, minority women are more likely to be diagnosed with more advanced-stage breast cancer and receive inappropriate treatment, a new study has found.

Study finds some individuals have genetic variants that allow them to have long-term exposure to a carcinogen without developing lung cancer.

The PD-1 agent nivolumab (Opdivo) was FDA approved October 9 for patients with non-squamous non-small cell lung cancer (NSCLC) whose cancer progressed during or following platinum-based chemotherapy.